FDA Approves Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 Vaccine
Pfizer and BioNTech have announced that the U.S. Food and Drug Administration (FDA) has approved their supplemental Biologics License Application
Read morePfizer and BioNTech have announced that the U.S. Food and Drug Administration (FDA) has approved their supplemental Biologics License Application
Read moreSangamo Therapeutics Enters License Agreement with Genentech to Develop Genomic Medicines for Neurodegenerative Diseases Sangamo Therapeutics, Inc., a leader in
Read moreJohnson & Johnson (NYSE: JNJ) has announced promising outcomes from its Phase 3 Vivacity-MG study, evaluating Nipocalimab in patients with
Read morePfizer and BioNTech have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the
Read moreResearchers have devised a novel human 3D model for Alzheimer’s Disease, enabling the study of immune cell involvement in the
Read moreBritish pharma giant GSK has announced positive results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab
Read moreIn a forward-thinking move, Sanofi, Formation Bio, and OpenAI have joined forces to harness the power of artificial intelligence in
Read moreThe approval is supported by robust clinical evidence, including results from a global Phase III trial. Omlyclo® is the first
Read moreTakeda has secured an exclusive global option and license agreement for AC Immune’s promising active immunotherapy targeting amyloid beta for
Read moreIn this partnership, Boehringer Ingelheim will utilise specific US-based pharmacy store chain Walgreens sites for clinical trials focusing on individuals
Read more